The assessment by Douglas Manuel and associates1 of the 2003 Canadian dyslipidemia
guidelines2 is welcome, but they overlooked the all-cause mortality issue, where statins …

The assessment by Douglas Manuel and associates1 of the 2003 Canadian dyslipidemia
guidelines2 is welcome, but they overlooked the all-cause mortality issue, where statins …

The assessment by Douglas Manuel and associates1 of the 2003 Canadian dyslipidemia
guidelines2 is welcome, but they overlooked the all-cause mortality issue, where statins …

The assessment by Douglas Manuel and associates1 of the 2003 Canadian dyslipidemia
guidelines2 is welcome, but they overlooked the all-cause mortality issue, where statins …

See related research article by Tonelli and colleagues at www. cmaj. ca/lookup/doi/10.1503/
cmaj. 101280 and synopsis on page 1845, and related research article by Conly and …

In considering whether a patient should be placed on a preventive medication, the focus
should be on outcomes that balance risks and benefits to the patientrather than outcomes …

on mortality and reduced coronary events only a modest 21% but increased abnormal liver
function 6-fold (4). Extrapolating from on mortality and reduced coronary events only a …

This discussion was sparked by an editorial critique by Sniderman et al 1 regarding the
2010 Cholesterol Treatment Trialists'(CTT) meta-analysis that suggested a statin …

It is unfortunate that in their Counterpoint Sniderman et al digress from the issue of mortality.
To reiterate, all trials in which investigators used a placebo in women failed, as stated in the …

Using statins for the primary prevention of cardiovascular disease (CVD) in low-risk
individuals is associated with additional drug costs of about $1/day per person; however, it …